Novo Nordisk : Q2 2020 disrupted by COVID-19
>Q2 2020: Sales 2% below, EBIT 3% above expectations - Novo Nordisk's H1 2020 publication reflects a Q2 2020 2% below expectations on sales but 3% above consensus on operating profit. In detail, sales are stable compared to the corresponding period of last year on a reported basis. On first reading, the group blames COVID-19 with fewer patients initiating treatment during the quarter but also a destocking effect due to inventories built up in Q1 by patients in anticip...Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.